For Research Use Only. Not for human consumption. The following summarizes published preclinical literature for laboratory research purposes only.
What It Is
KLOW is a combination research compound blending four distinct peptides that are individually studied in the published tissue-repair and dermatological literature: BPC-157, TB-500 (Thymosin Beta-4), KPV, and GHK-Cu (copper tripeptide). The name is an acronym drawn from the four components. It is not itself a naturally occurring single molecule or a peptide sequence studied as one unit in the literature; rather, it is a laboratory blend formulated by resellers to allow researchers to study these four peptide compounds together in vitro. No published studies to date examine this specific four-peptide combination as a unit — the research base referenced below pertains to each individual component studied independently.
Component Research Summaries
BPC-157: A synthetic 15-amino-acid pentadecapeptide most extensively studied in rat models of gastric ulcer protection and tendon/ligament healing. Key findings include accelerated Achilles tendon-to-bone healing in transection and corticosteroid-aggravation rat models (PMID 16583442) and significant ulcer-area reduction in gastric injury models (World Journal of Gastroenterology). Proposed mechanisms center on nitric oxide system modulation and angiogenesis support.
TB-500 (Thymosin Beta-4): A synthetic analog of the naturally occurring actin-regulating protein Thymosin Beta-4, studied in rat ligament repair models (improved collagen organization and biomechanical strength, PMID 23523891) and corneal/dermal wound-healing animal models (accelerated re-epithelialization, PMC2701135). Proposed mechanisms involve cell migration support via actin sequestration and reduced inflammatory signaling.
KPV: A tripeptide fragment (Lysine-Proline-Valine) derived from the C-terminal region of alpha-melanocyte-stimulating hormone (α-MSH), specifically the α-MSH(11–13) sequence. It is studied in murine models of inflammatory bowel disease. In a key study, KPV treatment in DSS-induced and CD45RB(hi)-transfer colitis mouse models led to earlier weight recovery, reduced histological inflammatory infiltrates, and significantly lowered colonic myeloperoxidase (MPO) activity — a marker of neutrophil-driven inflammation — with effects observed even in mice lacking a functional melanocortin-1 receptor, suggesting a partially receptor-independent anti-inflammatory pathway (Inflammatory Bowel Diseases, 2008, PMID 18092346).
GHK-Cu: A naturally occurring copper-binding tripeptide (Glycyl-L-Histidyl-L-Lysine) present in human plasma and released from tissue during injury. It is heavily studied for effects on gene expression relevant to tissue remodeling: research indicates GHK influences expression of roughly a third of measured human genes, modulating collagen, elastin, and glycosaminoglycan synthesis pathways in dermal fibroblast studies (International Journal of Molecular Sciences, 2018). Additional review literature describes GHK’s proposed role as a signal peptide released from proteolytic breakdown of type I collagen during injury, first proposed by Maquart et al. in the 1980s (PMC4508379).
Proposed Mechanism of Action (Combined Blend)
No published mechanistic study evaluates these four peptides administered together; the rationale for combining them in a research blend is based on the individual literature above spanning overlapping but distinct pathways — nitric oxide/angiogenesis modulation (BPC-157), actin-mediated cell migration (TB-500), melanocortin-pathway anti-inflammatory signaling (KPV), and copper-dependent gene expression/collagen remodeling (GHK-Cu). Any combined effects of simultaneous exposure remain an open research question requiring dedicated in-vitro or in-vivo study design rather than extrapolation from single-peptide data.
Glow Blend vs KLOW: Comparing the Two Formulations
Ascenyx Bio separately lists a related three-peptide formulation, Glow Blend, and researchers frequently ask how it differs from KLOW. The distinction is compositional, not a matter of concentration or grade: KLOW is a four-peptide blend that includes KPV alongside GHK-Cu, BPC-157, and TB-500 (Thymosin Beta-4), while Glow Blend combines only the latter three components, in a different mass ratio. Vendor naming across the research-peptide market is inconsistent — some sellers use “KLOW” for a three-peptide mix, and others sell “Glow Blend”-style products that include KPV — so the peptide list on a lot’s Certificate of Analysis is the only reliable way to confirm what a given vial contains, not the marketing name attached to it.
The table below compares each product’s most recent batch-specific analytical data, verified by independent HPLC-UV/LC-MS testing:
| Attribute | KLOW 80mg | Glow Blend 70mg |
|---|---|---|
| Components | GHK-Cu, KPV, BPC-157, Thymosin Beta-4 (TB-500) | GHK-Cu, BPC-157, Thymosin Beta-4 (TB-500) |
| Label claim | 80 mg total | 70 mg total |
| Verified net content | GHK-Cu 54.29 mg / KPV 10.89 mg / BPC-157 10.12 mg / Thymosin Beta-4 12.00 mg (lot AX-072326-001) | GHK-Cu 54.84 mg / BPC-157 13.98 mg / Thymosin Beta-4 11.06 mg (lot AX-GL70-081026-001) |
| Verified purity (HPLC-UV) | 99.57% | 99.75% |
| Identity confirmation | LC-MS, all four components confirmed | LC-MS, all three components confirmed |
Both figures come from Certificates of Analysis issued by an independent testing lab for the specific lots referenced above; other lots may show different net-content figures within the same specification, which is why we publish a batch-specific COA for every lot rather than a single static specification sheet. Researchers comparing the two products should note that removing KPV from the Glow Blend formulation proportionally increases the relative share of BPC-157 and Thymosin Beta-4 in the total mass, changing the molar ratio of components under study even though three of the four peptides overlap. See our guide on how to read a peptide Certificate of Analysis for a full walkthrough of these fields, or browse the COA Library directly for current lot documentation on both products.
Research Use Only / Handling Note
KLOW is supplied as a lyophilized powder blend intended solely for laboratory and in-vitro research use. This product is not a drug, supplement, or cosmetic and is not intended for human or animal consumption.